Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia

Launched by THE UNIVERSITY OF HONG KONG · Dec 21, 2021

Keywords

ClinConnect Summary

This clinical trial, called the MainRexult study, is looking at how well a combination treatment of two medications, Abilify Maintena and Rexulti, works for people with schizophrenia and related disorders. The goal is to see how effective and tolerable this treatment is in real-life situations, meaning how it performs outside of a controlled research environment. Researchers are currently recruiting participants who are between 18 and 65 years old and have been diagnosed with specific types of schizophrenia or similar conditions.

To participate, individuals must be able to read and communicate in English or Chinese and give their consent to be a part of the study. Participants will have been receiving the combination treatment for no more than eight weeks when they join the trial. Those who take part can expect to help researchers understand the benefits and side effects of this treatment combination, which may ultimately improve care for others with similar conditions. It's important to note that individuals with intellectual disabilities or those under 18 are not eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: 18- 65 years old at the time of enrollment
• • Able to read and communicate in English and/or Chinese
• • Able to give informed consent
• • Has been diagnosed to have Schizophrenia (DSM-5 or ICD-10 F20 \[except F20.81\], Schizotypal (Personality) Disorder (DSM-5 or ICD-10 F21), or Schizoaffective Disorder (DSM-5 or ICD-10 F25), (Persistent) Delusional Disorder (DSM-5 or ICD-10 F22), Schizophreniform Disorder (DSM-5 or ICD-10 F20.81), Brief Psychotic Disorder (DSM-5) or Acute and Transient Psychotic Disorder (ICD-10 F23)
• • Is receiving the combination with Abilify Maintena and brexpiprazole as treatment ≤8 weeks at the time of recruitment
• Exclusion Criteria:
• • Age \<18 years old
• • Unable to read English or Chinese
• • Unable to give informed consent
• • Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation (ICD-10 F70-73)